Fw: Special Edition: Release of the 2011 Hepatitis Pipeline Report

[Guest guest]

From: "Treatment Action Group" <Treatment_Action_Group@...>Date: Wed, 09 Mar 2011 16:53:01 +0000<powertx@...>Reply "Treatment Action Group" <reply-b5f575334e-0b5caff394-ca5e@...>Subject: Special Edition: Release of the 2011 Hepatitis Pipeline Report TAG's e-Newsletter Special EditionMarch 2011 Treatment Action GroupreleasesThe Hepatitis C Treatment Pipeline Report FDA approval of two hepatitis C-specific protease inhibitors, the first of the coming wave of oral antiviral drugs, is anticipated later this year. Dozens of drugs are in development to fight hepatitis C virus (HCV). Treatment Action Group is pleased to present the 2011 Hepatitis C Treatment Pipeline Report, an overview of drugs in clinical trials. The Pipeline covers a range of issues, including diagnostics, drug resistance, access to, and delivery of treatment, and population-specific focus on the new HCV drugs, as well as TAG's research recommendations. Download your copy ofThe Hepatitis C Treatment Pipeline Report Treatment Action Group (TAG) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG’s programs focus on antiretroviral treatments, HIV basic science and immunology, vaccines and prevention technologies, hepatitis, and tuberculosis. TAG is a not-for-profit organization founded in 1992 and based in New York City. Visit us at www.treatmentactiongroup.org If you no longer wish to receive these emails, please reply to this message with "Unsubscribe" in the subject line or simply click on the following link: UnsubscribeClick here to forward this email to a friendTreatment Action Group611 Broadway Suite 308New York, New York 10012USRead the VerticalResponse marketing policy.